. Author manuscript; available in PMC: 2021 Jun 17.

Published in final edited form as: Lancet Haematol. 2017 Mar 20;4(5):e225–e236. doi: 10.1016/S2352-3026(17)30027-3

Table 2:

Patients in the intention-to-treat and evaluable populations overall and by prespecified baseline platelet subgroups who achieved ≥35% reduction in spleen volume at week 24

	Intention-to-treat			Evaluable
	Pacritinib	BAT	p value	Pacritinib	BAT	p value
Overall	42/220 (19%)	5/107 (5%)	0∙0003	42/168 (25%)	5/85 (6%)	0∙0001
Platelets
<100 000/μL	12/72 (17%)	0/34	0∙0086	12/51 (24%)	0/24	0∙0072
<50 000/μL	8/35 (23%)	0/16	0∙045	8/24 (33%)	0/11	0∙037

Data are n/N (%).